1Ross R. Atherosclerosis--an inflammatory disease[J]. N Engl J Med,1999,340(2): 115 126.
2Steinberg D. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime [J]. Nat Med,2002,8(ll): 1211 1217.
3Vendrov AE, Hakim ZS, Madamanchi NR, et al. Atheroselerosis is attenuated by limiting superoxide generation in both macrophages and vessel wall cells[J]. Arterioscler Thromb Vase Biol, 2007,27 ( 12 ) : 2714-2721.
7Platt N, Haworth R, Darley L,et al. The many roles of the class A macrophage scavenger reeeptor[J]. Int Rev Cytol, 2002,212:1-40.
8Febhraio M, Hajjar DP. Silverstein RL. CD36 : A class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism[J]. Clin Invest, 2001,108 (6) : 785-791.
9Suzuki H, Kurihara Y, Takeya M, et al. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection I-J . Nature, 1997, 386 ( 6622 ) : 292-296.
10Febbraio M, Podrez EA, Smith JD, et al. Targeted disruption of the class B scavenger receptor CD36protects against atheroselerotic lesion development in mice[J]. Clin Invest, 2000,105(8) : 1049-1056.
7IJUSCHER T F,BARTON M. Biology of the endothelium[J].Clinical cardiology, 1997,20(11 Suppl 2) :II-3-10.
8KINLAY S, LIBBY P, GANZ P. Endothelial function and coronary artery disease[J]. Current opinion in lipidol- ogy ,2001,12(4) : 383-9.
9ZAMPETAKI A, DUDEK K, MAYR M. Oxidative stress in atherosclerosis: the role of microRNAs in arterial remodeling[J]. Free radical biology & medicine ,2013,64:69-77.
10BIR S C,SHEN X,KAVANAGH T J,et al. Control of angiogenesis dictated by picomolar superoxide Ievels[J]. Free radical biology & medicine, 2013,63: 135-42.
2Roh J,Chang CL, Bhalla A,et al. Intermedin is a calcitonin/ calcitonin gene-related peptide family peptide acting through the calcitonin recepto:like receptor/receptor activity- modifying protein receptor eomplexes[J]. J Biol Chem, 2004, 279(8) :7264-7274.
3Takei Y, Inoue K, Ogoshi M, et al. Identification of novel adrenomedullin in mammals: a potent cardiovascular and renal regulator[J]. FEBS Lett, 2004,556 (1-3) : 53-58.
4Yang JH,Jia YX, Pan CS, et al. Effects of intermedin(1-53) on cardiac function and ischemia/reperfusion injury in isolated rat heartsD]. Bioehem Biophys Res Commun, 2005,327(3): 713-719.
5Holmes D, Campbell M, Harbinson M, et al. Protective effects of intermedin on cardiovascular, pulmonary and renal diseases: comparison with adrenomedullin and CGRP[J]. Curr Protein Pept Sci, 2013,14(4) : 294- 329.
6Hong Y, Hay DL, Quirion R, et al. The pharmacology of adrenomedullin 2/intermedin[J]. Br J Pharmaeol, 2012, 166 (1):110-120.
7Zhang X, Gu L, Chen X, et al. lntermedin ameliorates atherosclerosis in ApoE null mice by modifying lipid profiles [J]. Peptides, 2012,37(2) : 189- 193.
8Dai XY, Cai Y, Mao DD, et al. Increased stability of phosphatase and tensin homolog by intermedin leading to scavenger receptor A inhibition of macrophages reduces atherosclerosis in apolipoprotein E-deficient mice[J]. J Mol Cell Cardiol, 2012,53(4) : 509-520.
9Wang Y, Yang R, Chen X, et al. Intermedin inhibits uptake of oxidized LDL via CD36 pathway in RAW264. 7 cells[J]. Pharmazie, 2014,69 (6) : 473- 476.
10Dai XY,Cai Y, Sun W, et al. Intermedin inhibits macrophage foam cell formation via tristetraprolin-mediated decay of CD36 mRNA[J]. Cardiovasc Res, 2014,101(2) : 297-305.
